ClinicalTrials.gg
CompletedNCT05978739Updated Jun 11, 2026

Evaluating Different Doses of Orelabrutinib in MCL

A Phase 2 interventional study of Orelabrutinib High dose and Orelabrutinib Low dose in Mantle Cell Lymphoma, sponsored by InnoCare Pharma Inc.. Completed at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by InnoCare Pharma Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.

Enrollment
55th of 91
40 · median 50
Started
2023
with 5 others
Phase 2
31 of 98
19 open now
Registered
61st of 98
by date

Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 55th largest by enrollment of the 91 interventional ones that give a count, is one of 6 that started in 2023, is one of 31 in phase 2, and was the 61st registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lymphoma, Mantle-Cell with a site in China, or all of them as a file.
02

Study summary

This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell Lymphoma.

03

Conditions studied

  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects ≥ 18 years of age.
  2. Mantle cell lymphoma (MCL) confirmed by histopathology.
  3. Subjects who have not previously received standard systemic care and relapsing/ subjects who have previously received standard systemic care.
  4. At least one .
  5. Physical fitness score 0-2 points.
  6. Expected survival time ≥ 4 months.
  7. Full hematology function.
  8. Blood clotting function is basically normal.
  9. Subjects with basically normal liver, kidney and heart function.
  10. Subject voluntarily signs a written ICF.
  11. The serum pregnancy test of female subjects with fertility potential was negative within 7 days before the first dosing.
  12. Female subjects with or male subjects and their partners must agree to use effective for at least 6 months from signing the ICF until the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Adequate treatment with BTK inhibitors.
  2. Have a history of severe allergic disease and a history of severe drug allergy.
  3. Subjects who have received the treatment or drug restricted in the protocol within the time specified for the first use of the drug.
  4. The last use of a potent inhibitor or potent CYP3A inducer (including food, western medicine, and Chinese medicine) was less than 2 weeks (or less than 5 half-lives, depending on the time) from the first trial, or plan to take a potent CYP3A inhibitor or potent CYP3A inducer drug or food during the study period.
  5. History of other active malignant diseases within 2 years prior to screening.
  6. Subjects with systemic bacterial, viral, fungal (other than nail fungal infections) or parasitic infections with poorly controlled activity.
  7. Indicates active or C virus infection.
  8. There are diseases that are excluded from the criteria in the programme.
  9. Toxicity of previous anticancer therapy was still ≥ grade 2 at the start of study therapy (according to V5.0).
  10. History of severe bleeding disorder.
  11. People with a known history of alcohol or drug abuse.
  12. Subjects with mental disorders or poor compliance.
  13. Pregnant or lactating female subjects.
  14. Other conditions deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Orelabrutinib high dose

    Drug: Orelabrutinib High dose

  • Experimental
    Orelabrutinib low dose

    Drug: Orelabrutinib Low dose

Interventions

  • DrugOrelabrutinib High dose

    Orelabrutinib will be administered as 3 tablets once per day

  • DrugOrelabrutinib Low dose

    Orelabrutinib will be administered as 1 tablet once per day

06

What researchers measure

Primary outcomes

  1. Objective response rate(ORR)

    Proportion of subjects with tumor response of Complete Response(CR) or Partial Response(PR) after treatment in total subjects.

    Time frame: Through study completion, an average of 2 year

Secondary outcomes

  1. Complete Response Rate (CRR)

    The proportion of subjects with tumor response of Complete Response(CR) after treatment in total subjects.

    Time frame: Through study completion, an average of 2 year

  2. Progression-Free Survival (PFS)

    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first.

    Time frame: Through study completion, an average of 2 year

  3. Duration of Response (DoR)

    The time from documentation of objective response to the first occurrence of tumor progression or death due to any cause, whichever occurs first.

    Time frame: Through study completion, an average of 2 year

  4. Maximum concentration (Cmax,ss)

    Time frame: Predose up to 24 hours postdose

  5. Time to maximum concentration (Tmax)

    Time frame: Predose up to 24 hours postdose

  6. Area under the plasma concentration-time curve (AUC)

    Time frame: Predose up to 24 hours postdose

  7. Half-life (T1/2)

    Time frame: Predose up to 24 hours postdose

  8. Apparent clearance (CL/F)

    Time frame: Predose up to 24 hours postdose

  9. Adverse events(AEs)

    Time frame: Through study completion, an average of 2 year

  10. Serious adverse events (SAEs)

    Time frame: Through study completion, an average of 2 year

07

Study locations

20 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233040, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • Sun Yat-sen University Cancer Center
    Guangdong, Guangzhou 510055, China
  • Nanyang Second General Hospital
    Nanyang, Henan 473009, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Union Hospital Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
  • Chenzhou First People's Hospital
    Chenzhou, Hunan 423003, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 330029, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116023, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710004, China
  • The Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, Uygur Autonomous Region 830000, China
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Dec 2024, 15 months.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 15 months is below that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Aug 7, 2023
StartActual
Aug 18, 2023
Primary completionActual
Dec 10, 2024
CompletionActual
Dec 10, 2024
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05978739
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Aug 18, 2023
Primary completion
Dec 10, 2024
Completion
Dec 10, 2024
Last update
Jun 11, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion